ClinicalTrials.gg
Enrolling by invitationNCT07747194Updated Aug 5, 2026

Acupuncture to Prevent Nausea and Vomiting After Stem Cell Transplant

An interventional study of Acupuncture and Conventional care in Chemotherapy-Induced Nausea and Vomiting (CINV) and Hematopoietic Stem Cell Transplantation (HSCT), sponsored by Xiao Wang. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Xiao Wang · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is testing whether acupuncture at a point on the wrist called "Neiguan" can help reduce nausea and vomiting in patients undergoing stem cell transplantation. Participants will receive either real acupuncture or standard care. We hope to find a safe way to improve comfort during cancer treatment.

02

Conditions studied

  • Chemotherapy-Induced Nausea and Vomiting (CINV)
  • Hematopoietic Stem Cell Transplantation (HSCT)

Browse trials for

Keywords

  • Acupuncture
  • Hematopoietic Stem Cell Transplantation
  • Neiguan
03

In context

Vomiting

793 studies on the registry are indexed under Vomiting; 99 are open to participants now.

This study's planned enrollment of 80 is below the median of 103 across 673 interventional studies indexed under Vomiting.

Browse Vomiting studies →

Lead sponsor

Xiao Wang is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age 18-65 years, either sex. Patients scheduled to receive a conditioning (preparative) regimen for hematopoietic stem cell transplantation ().

≥ 3 months. (ECOG) performance status of 0-2. Women of must have a negative pregnancy test (serum or urine) within 7 days prior to enrollment.

Voluntary participation with signed .

Exclusion criteria

Exclusion Criteria:

Received chemotherapy with highly emetogenic agents within 14 days prior to enrollment.

Received radiotherapy within 7 days prior to enrollment, or planned radiotherapy during the study period.

Known to any study drug or its . Complicated with gastrointestinal obstruction, with symptoms of increased intracranial pressure, or any other condition that may cause and/or exacerbate nausea and vomiting.

Active infection. Unable to take oral medications. Use of any anti-emetic medication (including ) within 48 hours or 5 half-lives of the drug (whichever is longer) prior to enrollment.

Any episode of nausea, vomiting, or retching within 24 hours prior to the first administration.

Severe psychiatric illness or cognitive impairment that precludes understanding, reading, and completing patient diaries.

Any other condition that the investigator deems would make the patient unsuitable for participation in this study.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Acupuncture at Neiguan

    Procedure: Acupuncture

  • Active comparator
    Standard Care

    Drug: Conventional care

Interventions

  • ProcedureAcupuncture

    Add-on manual acupuncture at bilateral Neiguan (PC6) to standard quadruple anti-emetic prophylaxis. Disposable sterile acupuncture needles inserted perpendicularly 0.5-1 cun (approximately 10-25 mm) into Neiguan with even reinforcing-reducing manipulation; needles retained for 30 minutes. Administered once daily throughout the conditioning (preparative) regimen. This distinguishes the intervention from: (1) the active comparator arm in this study, which receives identical pharmacological prophylaxis without acupuncture; and (2) other acupuncture trials that may use electroacupuncture, different acupoints, variable needle depths, or shorter treatment durations.

  • DrugConventional care

    Standard quadruple pharmacological anti-emetic prophylaxis comprising a 5-HT3 receptor antagonist, an NK-1 receptor antagonist, dexamethasone, and olanzapine, administered per institutional HSCT supportive care protocol. No acupuncture or sham procedure is provided. This distinguishes the arm from the experimental arm, which receives the identical pharmacological regimen plus add-on manual acupuncture at Neiguan (PC6).

06

What researchers measure

Primary outcomes

  1. Incidence and severity of nausea and vomiting during the conditioning regimen for hematopoietic stem cell transplantation

    Time frame: Throughout the conditioning period (approximately 3-7 days)

Secondary outcomes

  1. Nutritional status assessed by serum albumin and prealbumin levels

    Time frame: Baseline (pre-conditioning), Day 7, Day14, and Day 28 of conditioning, and Day 30 post-transplant

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07747194
Lead sponsor
Xiao Wang
Responsible party
Xiao Wang (Attending Physician, The General Hospital of Western Theater Command) — Sponsor-investigator
First posted
Aug 5, 2026
Start date
Jul 1, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Aug 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion